论文部分内容阅读
目的:观察艾迪注射液联合动脉灌注化疗(TAI)治疗肝转移瘤的近期疗效和不良反应。方法:将68例肝转移瘤患者随机分为对照组和治疗组,治疗组(34例)动脉灌注化疗联合应用艾迪注射液治疗,对照组单纯接受动脉灌注化疗,比较两组经6个治疗周期前后肿瘤的大小、Karnofsky评分、胃肠道反应和骨髓抑制。结果:治疗组近期有效率50.0%对照组41.8%,统计学无显著性差异(P>0.05);治疗组的生存质量、胃肠道反应和骨髓抑制均优于对照组,统计学有显著性差异(P<0.05)。结论:艾迪注射液联合动脉灌注化疗,对改善肝转移瘤患者生存质量和减少化疗药物的不良反应有一定作用。
Objective: To observe the short-term curative effect and adverse reaction of Aidi injection combined with arterial infusion chemotherapy (TAI) in the treatment of liver metastases. Methods: Sixty-eight patients with liver metastases were randomly divided into control group and treatment group. The treatment group (34 cases) was given arterial infusion chemotherapy combined with Aidi Injection. The control group received only arterial infusion chemotherapy. Tumor size before and after the cycle, Karnofsky score, gastrointestinal reaction and myelosuppression. Results: The effective rate of the treatment group was 50.0%, 41.8% in the control group, there was no significant difference (P> 0.05). The quality of life, gastrointestinal reaction and myelosuppression in the treatment group were better than those in the control group Difference (P <0.05). Conclusion: Aidi injection combined with intraarterial infusion chemotherapy has some effect on improving the quality of life of patients with liver metastases and reducing the adverse reactions of chemotherapy drugs.